top stories

No­var­tis scores its lat­est FDA OK — this time for a new sick­le cell dis­ease drug picked up in a $665M deal

5 hours ago
R&D

UP­DAT­ED: In a first, FDA green-lights use of a Chi­nese built can­cer ther­a­py — and more are com­ing

Yesterday
China
Regulatory

UP­DAT­ED: Roche bags 'break­through' an­ti-fi­bro­sis drug in $1.4B biotech buy­out deal

13 hours ago
Deals
R&D

As­traZeneca gains EU nod for di­a­betes triple; Am­gen and Duke launch re­al-world PC­SK9 ob­ser­va­tion­al study

10 hours ago
Protocols

Latest

Five drugs, in­clud­ing two No­var­tis ther­a­pies, win EMA en­dorse­ment

11 hours ago
R&D
Regulatory

Atom­wise's X-37 spin­out gets $14.5 mil­lion to launch AI dis­cov­ery ef­forts

11 hours ago
R&D

Ab­bott Lab­o­ra­to­ries CEO Miles White pass­es ba­ton down to suc­ces­sor; Lon­za CEO Marc Funk hits the ex­it

11 hours ago
Peer Review

UCB adds on more pos­i­tive PhI­II da­ta for IL-17A/17F in­hibitor bimek­izum­ab, clear­ing a path to the FDA

12 hours ago
R&D

EMA fi­nal­izes clin­i­cal de­vel­op­ment guide­line for new gout treat­ments

12 hours ago
Regulatory

No­var­tis spin­out’s first an­ti-ag­ing PhI­II is a flop, so now they’ll turn to Parkin­son’s chal­lenge as shares ...

13 hours ago
R&D
see latest stream
People

Flag­ship woos No­var­tis top deal­mak­er Prakash Ra­man in move to get the BD ball rolling ear­ly

3 days ago

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

4 days ago

An­oth­er ex-Shire re­search ex­ec heads out, grab­bing top R&D job at deal-hun­gry Ipsen as post-buy­out ex­o­dus con­tin­ues

Last week
Startups

New cell ther­a­py play­er launch­es with $57M from mar­quee in­vestors to go af­ter 'de­fin­i­tive' tu­mor tar­gets

Last week

New UK start­up pur­sues off-the-shelf CAR-T, can­cer vac­cines through 'dark anti­gen­s'

Last week

Some bat­tle test­ed neu­ro­science vets are go­ing all out on ear­ly on­set de­men­tia — with a $44M launch round to build ...

Last week
Deals

Sarep­ta picks up a slate of pre­clin­i­cal gene ther­a­py pro­grams, seed­ing new Stride­Bio deal with $48M up­front

Yesterday

Al­ler­gan en­lists Ex­i­cure in search of hair loss drugs with $25M up­front, dou­bling down on area dear to Ab­b­Vie

Yesterday

Take­da dou­bles down on Finch's mi­cro­bio­me in­sights, sign­ing up for a sec­ond project in Crohn's dis­ease

2 days ago
IPOs

Tot Bio­pharm com­pletes HKEX list­ing, rais­ing $63M in mod­est de­but

Last week

Monopar de­lays IPO again de­spite slash­ing of­fer­ing while a mi­cro-cap biotech clinch­es $9M

Last week

Te­va spin­out de­lays NASH IPO while Galera prices be­low range

Last week

Premium storiesSee all

Alzheimer's break­through? Not so fast — ex­perts poke holes in da­ta un­der­ly­ing Chi­na's sur­prise ap­proval

Last week
China

As CRISPR hori­zons cloud, a start­up fo­cus­es on the next big thing with pow­er­house po­ten­tial — the RNA edit­ing ...

Last week
Startups

Worth­less? Short at­tack on Fi­bro­Gen claims their ane­mia drug roxa has a lethal Achilles’ heel — and it’s go­ing ...

Last week
Pharma
R&D

Vivek Ra­maswamy trades top ex­ecs and adds stealthy vant to $3B sale, while his new part­ner toss­es My­ovant $350M

3 weeks ago
Deals

Don't missSee all

Amarin emerges from an ex­pert pan­el re­view with a clear en­dorse­ment for Vas­cepa and high odds of suc­cess when the FDA ...

Yesterday
Regulatory

What does $62B buy you these days? A lot, says Take­da ex­ecs as the phar­ma play­er promis­es a block­buster R&D fu­ture

Yesterday
R&D

FDA pan­el large­ly op­pos­es ex­pand­ing use of Lil­ly, Boehringer's SGLT2 in­hibitor to type 1 di­a­bet­ics

Yesterday
Pharma
R&D

Bay­er bets up to $100M on ex­plor­ing new bio­mol­e­c­u­lar con­den­sate ter­rain with a biotech up­start

Yesterday
R&D

Endpoints Standouts

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

4 days ago
People
R&D

The $102B club: The top 15 R&D spenders in the glob­al bio­phar­ma busi­ness — 2019 edi­tion

Last month
R&D

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

Last month

[Video] Putting the AI in R&D — with Badhri Srini­vasan, Tony Wood, Rosana Kapeller, Hugo Ceule­mans, Saurabh Sa­ha ...

2 months ago
AI

Peer review See all

Nov
8

An­ces­tryD­NA chief takes on liq­uid biop­sy chal­lenge; Thomas Lynch chairs for­mer col­league's can­cer start­up

Nov
1

Gilead­'s ex-in­vestor re­la­tions chief takes CFO job at Sang­amo; For­mer GE Health­care ex­ec takes the helm at Vec­tura Group

Oct
25

Christo­pher Haqq joins Eli­cio to hunt fa­ther's RAS can­cer; Kro­nos ex­pands top team with Gilead, Bay­lor vets

Oct
18

Ronald Herb­st fol­lows Med­Im­mune ex­o­dus to Pyx­is CSO post; Jeff God­dard to suc­ceed CEO of AIT Bio­science

Oct
11

Zosano Phar­ma CEO pass­es ba­ton down to suc­ces­sor; James Sapirstein takes the helm at Azur­Rx

R&D channel feed

2 days ago

GSK's asth­ma bi­o­log­ic Nu­cala scores in rare blood dis­or­der study

Glax­o­SmithK­line's asth­ma drug Nu­cala, which re­ceived a re­sound­ing FDA re­jec­tion for use in chron­ic ob­struc­tive pul­monary dis­ease (COPD) last year, has shown promise in a rare blood ...

READ MORE

Mer­ck buys a fledg­ling neu­rode­gen­er­a­tive biotech spawned by an old GSK dis­cov­ery al­liance. What’s up with that?

2 days ago
Deals

FDA Vas­cepa re­view spot­lights new safe­ty sig­nals, pos­si­ble min­er­al oil spoil­er as Amarin hunts a block­buster ap­proval

3 days ago
latest in R&D

Af­ter pos­i­tive pan­el vote, Sh­iono­gi an­tibi­ot­ic scores US ap­proval

14 hours ago

Shorts ga­lore: Mud­dy Wa­ters sees slide for Pep­tiDream, tweets con­cerns about Fi­bro­Gen's new da­ta

Yesterday

Pin­cer move­ment: Cal­i­for­nia biotech gets $35M to suf­fo­cate can­cer in co­or­di­nat­ed at­tack

Yesterday

Lit­tle biotech’s stock flat­lines as its fol­lowup at­tempt at a de­pres­sion drug tri­al win ends in an­oth­er de­feat

Yesterday

As­traZeneca, Mer­ck win red car­pet treat­ment at the FDA as a 3-time los­er seeks speedy OK for rare tu­mors

Yesterday
see latest stories

Pharma channel feed

3 days ago

Mer­ck shut­ters French re­search site in a re­or­ga­ni­za­tion aimed at elim­i­nat­ing more than 200 jobs

Mer­ck is shut­ter­ing a tox­i­col­o­gy re­search cen­ter in cen­tral France and scal­ing back on its man­u­fac­tur­ing op­er­a­tions in the area, lay­ing off more than 200 staffers in the process. La ...

READ MORE

Vot­ers say Con­gress needs to curb drug prices. So why do the odds look grim for ma­jor leg­is­la­tion this year?

3 days ago

FDA to re­voke or­phan des­ig­na­tion for opi­oid ad­dic­tion drug Sublo­cade

4 days ago
Regulatory
latest in Pharma

Fol­low­ing a win for Baven­cio, Pfiz­er and Mer­ck KGaA con­tin­ue PD-L1 los­ing streak

Last week
R&D

Eye­ing sec­ond Japan­ese ap­proval, Dai­ichi and Ex­elix­is an­nounce pos­i­tive piv­otal for kid­ney drug

Last week
R&D

Tri­fec­ta of in­com­ing mi­graine meds must be cheap­er than trip­tans to be cost-ef­fec­tive — ICER

Last week

Durbin push­es for Sen­ate vote on bill to in­clude drug prices in ads

Last week

Ear­ly da­ta on Takeda's dengue vac­cine is promis­ing, but wait for the full dataset

Last week
R&D
see latest stories